



Texas Task Force on Infectious Diseases Preparedness & Response

Peter Hotez, M.D., Ph.D.

Texas Children's Hospital Endowed Chair in Tropical Pediatrics

Dean, National School of Tropical Medicine at Baylor College of Medicine

U.S. Science Envoy
@PeterHotez



From the MDGs to the SDGs




2000-15 MDGs



2016 SDGs

The Millennium Development Goals



1. Eradicate extreme poverty and hunger.
2. Achieve universal primary education.
3. Promote gender equality and empower women.
4. Reduce child mortality.
5. Improve maternal health.
6. Combat HIV/AIDS, malaria, and other diseases.
7. Ensure environmental sustainability.
8. Develop a global partnership for development.



The Global Burden of Disease Study

Articles



REDUCE
CHILD MORTALITY

Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010

Rafael Lozano, Mohsen Naghavi, Kyle Foreman, Stephen Lim, Kenji Shibuya, Victor Aboyans*, Jerry Abraham*, Timothy Adair*, Rakesh Aggarwal*, Stephanie Y Ahn*, Miriam Alvarado*, H Ross Anderson*, Laurie M Anderson*, Kathryn G Andrews*, Charles Atkinson*, Larry M Baddour*, Suzanne Barker-Coll*, David H Bartels*, Michelle L Bell*, Emelia J Benjamin*, Derrick Bennett*, Kavi Bhalla*, Boris Bikbov*, Aref Bin Abdulhak*, Gretchen Birbeck*, Fiona Blyth*, Ian Bolliger*, Soufiane Boufous*, Chiara Bucello*, Michael Burch*, Peter Burney*, Jonathan Carapetis*, Honglei Chen*, David Chau*, Sumeet S Chugh*, Luc E Coffeng*, Steven D Colan*, Samantha Colquhoun*, K E Llicott Colson*, John Condon*, Myles D Connor*, Leslie T Cooper*, Matthew Corriere*, Monica Cortinovis*, Karen Courville de Vaccaro*, William Couser*, Benjamin C Cowie*, Michael H Criqui*, Marita Cross*, Kaustubh C Dabhadkar*, Nabila Dahodwala*, Diego De Leo*, Louisa Degenhardt*, Allyne Delossantos*, Julie Denenberg*, Don C Des Jarlais*, Samath D Dharmaratne*, E Ray Dorsey*, Tim Driscoll*, Herbert Duber*, Beth Ebel*, Patricia J Erwin*, Patricia Espindola*, Majid Ezzati*, Valery Feigin*, Abraham D Flaxman*, Mohammad H Forouzanfar*, Francis Gerry R Fowkes*, Richard Franklin*, Marlene Fransen*, Michael K Freeman*, Sherine E Gabriel*, Emmanuela Gakidou*, Flavio Gaspari*, Richard F Gillum*, Diego Gonzalez-Medina*, Yara A Halasa*, Diana Haring*, James E Harrison*, Rasmus Havmoeller*, Roderick J Hay*, Bruno Hoen*, Peter J Hotez*, Damian Hoy*, Kathryn H Jacobsen*, Spencer L James*, Rashmi Jasrasaria*, Sudha Jayaraman*, Nicole Johns*, Ganesan Karthikeyan*, Nicholas Kassebaum*, Andre Keren*, Jon-Paul Khoo*, Lisa Marie Knowlton*, Olive Kobusingye*, Adofo Koranteng*, Rita Krishnamurthi*, Michael Lipnick*, Steven E Lipshultz*, Summer Lockett Ohno*, Jacqueline Mabweijano*, Michael F MacIntyre*, Leslie Mallinger*, Lyn March*, Guy B Marks*, Robin Marks*, Akira Matsumori*, Richard Matzopoulos*, Bongani M Mayosi*, John H McAnulty*, Mary M McDermott*, John McGrath*, George A Mensah*, Tony R Merriman*, Catherine Michaud*, Matthew Miller*, Ted R Miller*, Charles Mock*, Ana Olga Mocumbi*, Ali A Mokdad*, Andrew Moran*, Kim Mulholland*, M Nathan Nair*, Luigi Naldi*, K M Venkat Narayan*, Kiumarss Nasserri*, Paul Norman*, Martin O'Donnell*, Saad B Omer*, Katrina Ortblad*, Richard Osborne*, Doruk Ozgediz*, Bishnu Pahari*, Jeyaraj Durai Pandian*, Andrea Panazo Rivera*, Rogelio Perez Padilla*, Fernando Perez-Ruiz*, Norberto Perico*, David Phillips*, Kelsey Pierce*, C Arden Pope III*, Esteban Porrini*, Farshad Pourmalek*, Murugesan Raju*, Dharani Ranganathan*, Jürgen T Rehm*, David B Rein*, Giuseppe Remuzzi*, Frederick P Rivara*, Thomas Roberts*, Felipe Rodriguez De León*, Lisa C Rosenfeld*, Lesley Rushton*, Ralph L Sacco*, Joshua A Salomon*, Uchechukwu Sampson*, Ella Sanman*, David C Schwebel*, Maria Segui-Gomez*, Donald S Shepard*, David Singh*, Jessica Singleton*, Karen Sliwa*, Emma Smith*, Andrew Steer*, Jennifer A Taylor*, Bernadette Thomas*, Imad M Tleyjeh*, Jeffrey A Towbin*, Thomas Truelsen*, Eduardo A Undurraga*, N Venketasubramanian*, Lakshmi Vijayakumar*, Theo Vos*, Gregory W Wagner*, Mengru Wang*, Wenzhi Wang*, Kerianne Watt*, Martin A Weinstock*, Robert Weintraub*, James D Wilkinson*, Anthony D Woolf*, Sarah Wulf*, Pon-Hsiu Yeh*, Paul Yip*, Azadeh Zabetian*, Zhi-Jie Zheng*, Alan D Lopez†, Christopher J L Murray†



The Global Burden of Disease 2013

Expanded use of vaccines

- 83% reduction in measles deaths
- 82% reduction in tetanus deaths
- 57% reduction in diphtheria/pertussis deaths
- 45% reduction in Hib deaths

Development new vaccines



- Pneumococcal disease (36% reduction in deaths)
- Rotavirus (63% reduction in deaths)

2.5 million childhood lives saved through these initiatives



TEXANS

for Vaccine Choice



- Texas ranks at the bottom of fully immunized children
- 45,000 Personal Belief Exemptions in Texas

The NEW ENGLAND JOURNAL of MEDICINE

ORIGINAL ARTICLE

Patches of Disorganization in the Neocortex of Children with Autism

Rich Stoner, Ph.D., Maggie L. Chow, Ph.D., Maureen P. Boyle, Ph.D.,
Susan M. Sunkin, Ph.D., Peter R. Mouton, Ph.D., Subhojit Roy, M.D., Ph.D.,
Anthony Wynshaw-Boris, M.D., Ph.D., Sophia A. Colamarino, Ph.D.,
Ed S. Lein, Ph.D., and Eric Courchesne, Ph.D.

ABSTRACT

BACKGROUND

Autism involves early brain overgrowth and dysfunction, which is most strongly evident in the prefrontal cortex. As assessed on pathological analysis, an excess of neurons in the prefrontal cortex among children with autism signals a disturbance in prenatal development and may be concomitant with abnormal cell type and



The Millennium Development Goals



1. Eradicate extreme poverty and hunger.
2. Achieve universal primary education.
3. Promote gender equality and empower women.
4. Reduce child mortality.
5. Improve maternal health.
6. Combat HIV/AIDS, malaria and other diseases.
7. Ensure environmental sustainability.
8. Develop a global partnership for development.






Global, regional, and national incidence and mortality for HIV, tuberculosis, and malaria during 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013

Christopher J L Murray*, Katrina F Ortblad, Caterina Guinovart, Stephen S Lim, Timothy M Wolock, D Allen Roberts, Emily A Dansereau, Nicholas Graetz, Ryan M Barber, Jonathan C Brown, Haidong Wang, Herbert C Duber, Mohsen Naghavi, Daniel Dicker, Lalit Dandona, Joshua A Salomon, Kyle R Heuton, Kyle Foreman, David E Phillips, Thomas D Fleming, Abraham D Flaxman, Bryan K Phillips, Elizabeth K Johnson, Megan S Coggeshall, Foad Abd-Allah, Semaw Ferede Abera, Jerry P Abraham, Ibrahim Abubakar, Laith J Abu-Raddad, Niveen Me Abu-Rmeileh, Tom Achoki, Austine Olufemi Adeyemo, Arsène Kouablan Adou, José C Adjuik, Emilie Elisabeth Agardh, Dickens Akena, Mazin J Al Khabouri, Deena Alsafoor, Mohammed I Albitar, Gabriel Alcalá-Carrat, Miguel Angel Alegretti, Zewdie Aderaw Alemu, Rafael Alfonso-Cristancho, Samia Alhabib, Raghib Ali, Francois Allat, Peter J Allen, Ubai Alsharif, Elena Alvarez, Nelson Alvis-Guzman, Adansi A Amankwaat, Azmeraw T Amaret, Hassan Aminit, Walid Ammar, Benjamin O Anderson, Carl Abelardo T Antonio, Palwasha Anwar, Johan Arnott, Valentina S Arsic Arsenijevic, Ali Artaman, Rana J Asghar, Reza Asadi, Lydia S Atkin, Alaa Badawi, Kalpana Balakrishnan, Amitava Banerjee, Sanjay Basu, Justin Beardslay, Tolesa Bekele, Michelle L Bell, Eduardo Bernabet, Tariku Jibat Beyene, Neeraj Bhalai, Ashish Bhalla, Zulfiqar A Bhutta, Aref Bin Abdulhak, Agnes Binagwahat, Jed D Blore, Dipan Bose, Michael Brainin, Nicholas Breitborde, Carlos A Castaneda-Orjuela, Ferrán Catalá-López, Vineet K Chadha, Jung-Chen Chang, Peggy Pei-Chia Chiang, Ting-Wu Chuang, Mercedes Colomari, Leslie Trumbull Cooper, Cyrus Cooper, Karen J Courville, Benjamin C Cowie, Michael H Criqui, Rakhi Dandona, Anand Dayama, Diego De Leo, Louisa Degenhardt, Borja Del Pozo-Cruz, Kebede Deribe, Dan C Des Jarlais, Mulken Dessalegn, Samath D Dharmaratne, Ugur Dilmen, Eric L Ding, Tim R Driscoll, Adnan M Durrani, Richard G Ellenbogen, Sergey Petrovich Ermakov, Alireza Esteghamati, Emerita Jose A Faraon, Farshad Farzadfar, Seyed-Mohammad Fereshtehnejad, Daniel Obadare Fijabif, Mohammad H Forouzanfar, Urbana Fra-Poleo, Lynne Gaffikin, Amiran Gamkrelidze, Fortuné Gbèdoho Gankpè, Johanna M Geleijnse, Bradford D Gessner, Katherine B Gibney, Ibrahim Abdelmageem Mohamed Ginawi, Elizabeth L Glaser, Philimon Gona, Atsushi Goto, Hebe N Gouda, Harish Chander Gugnani, Rajeev Gupta, Rahul Gupta, Nima Hafezi-Nejad, Randah Ribhi Hamadeh, Mouhanad Hammami, Graeme J Hankey, Hilda L Harb, Josep Maria Haro, Rasmus Havmoeller, Simon J Hay, Mohammad T Hedayati, Ilana B Heredia Pi, Hans WH Hoek, John C Hornberger, H Dean Hosgood, Peter J Hotze, Damian G Hoy, John J Huang, Kim M Iburg, Bulat T Idrisov, Kaire Innost, Kathryn H Jacobsen, Panniyammal Jeemon, Paul N Jensen, Vivekanand Jha, Guohong Jiang, Jost B Jonas, Knud Juel, Haidong Kan, Ida Kankindi, Nudim E Karami, André Karch, Corine Kakizi Karema, Anil Kaul, Norito Kawakami, Dhruv S Kazis, Andrew H Kemp, Andre Pascal Kengne, Andre Kerent, Maia Kereselidze, Yousef Saleh Khader, Shams Eldin Ali Hassan Khalifa, Ejaz Ahmed Khan, Young-Ho Khang, Irma Khondidze, Johannes Kinjot, Jonas M King, Luke Knibbs, Yoshihiro Kobayashi, S Kosen, Barthelmy Kurte Defo, Veena S Kulkarni, Chanda Kulkarni, Kaushalendra Kumar, Ravi B Kumar, Gene F Kwan, Taavi Lai, Arjun Lakshmana Balaji, Hilton Lam, Qing Lan, Van C Lansingh, Heidi J Larson, Anders Larsson, Jong-Tae Lee, James Leigh, Mall Leinsalu, Ricky Leung, Yichong Li, Yongmei Li, Graça Maria Ferreira De Lima, Hsien-Ho Lin, Steven E Lipschutz, Shiwel Liu, Yang Liu, Belinda K Lloyd, Paula A Lotufo, Vasco Manuel Pedro Machado, Jennifer H MacLachlan, Carlos Magis-Rodriguez, Marek Majdan, Christopher Chabila Mapoma, Wagner Marcenes, Melvin Barrientos Marzan, Joseph R Mascit, Mohammad Taufiq Mashat, Amanda J Mason-Jones, Bongani M Mayosi, Tasara T Mazorodze, Abigail Cecilia McKay, Peter A Meaney, Man Mohan Mehndiratta, Fabiola Mejia-Rodriguez, Johannes Adama Melaku,

- 19 million lives saved from AIDS
- 30% reduction in Malaria


Global Health Whack-a-Mole



“Other Diseases”

The Neglected Tropical Diseases

- 13-14 tropical infections:
 - Highly prevalent among the poor
 - Endemic in rural areas of low-income countries
 - Ancient afflictions
 - Chronic
 - Disabling (growth delays, blindness or disfigurement)
 - Stigmatizing
 - Poverty promoting




NTDs Global Burden Disease Study 2013-14

| | |
|----------------------------|----------------|
| • Ascariasis | 804.4 million |
| • Trichuriasis | 477.4 million |
| • Hookworm Disease | 471.8 million |
| • Schistosomiasis | 290.6 million |
| • Food-borne Trematodiasis | 80.2 million |
| • Dengue | 58.4 million |
| • Lymphatic Filariasis | 43.8 million |
| • Onchocerciasis | 17.0 million |
| • Chagas disease | 9.4 million |
| • Leishmaniasis | 4.0 million |
| • Zika | 4.0 million* |
| • Trachoma | 2.4 million |
| • Cysticercosis | 1.0 million |
| • Echinococcosis | 0.8 million |
| • Ebola | 28,000 |
| • Rabies | 23,500 |
| • African Trypanosomiasis | 19,700 |
| • Yaws | Not determined |
| • Buruli ulcer | Not determined |

NTD Scale up with the U.S. Government



USAID NTD Program



Africa:

Benin
Burkina Faso
Cameroon
DRC
Ghana
Guinea
Mali
Mozambique
Niger
Nigeria
Sierra Leone
Senegal
Tanzania
Togo
Uganda



Asia:

Bangladesh
Cambodia
Indonesia
Philippines
Lao PDR
Nepal
Vietnam

Americas:

Haiti

>450 million People Rx


Emergence of Dengue, Zika, and Chikungunya



Zika is an arbovirus and a flavivirus

FLAVIVIRUSES (ss +RNA)


- Dengue Virus
- Yellow Fever Virus
- Japanese Encephalitis Virus
- West Nile Virus
- St. Louis Encephalitis Virus
- Zika Virus




TRANSMITTED BY AEDES MOSQUITOES

- Dengue, YF but NOT WNV

Aedes mosquitoes including *Aedes aegypti* (humans) and *Ae. albopictus* (mammals, birds) in New World



Origins in the Zika Forest of Uganda



Zika means “Overgrowth”
Aedes africanus vector

Found in 1947
Virus Isolation published in 1952
First human case in Nigeria in 1954

14 cases in Africa

Zika Path: Explosive Pacific Outbreaks




What made Zika spread so quickly?

- Hypothesis 1: Something uniquely Zika*
 - “Pandemic strain” of Zika vs. African strain
 - Codon usage of NS1 gene
 - Increases fitness for replication in human host without changes in protein sequence
 - Codon usage by pandemic strains is optimized for replication in human cells
 - Higher viremias and increased infectivity for mosquitoes
 - Evolutionary strain

*Maj Gen Philip K Russell MD

Asian vs African Lineage

Nucleotide sequences from 41 strains were included in the analysis: 30 human isolates (including two newly reported here), ten mosquito isolates, and one monkey isolate.



From Mosquitos to Humans: Genetic Evolution of Zika Virus.


Wang L, Valderramos SG, Wu A, Ouyang S, Li C, Brasil P, Bonaldo M, Coates T, Nielsen-Saines K, Jiang T, Aliyari R, Cheng G. *Cell Host Microbe*. 2016 Apr 14. pii: S1931-3128(16)30142-1. doi: 10.1016/j.chom.2016.04.006. [Epub ahead of print]

Pre-M Protein

PrM protein of ZIKV shows significant structural alterations

PrM forms a heterodimer with the main viral surface protein, E, in the neutral pH of the lumen of the endoplasmic reticulum (ER)

The role of prM in viral pathogenesis has been under extensive investigation over the past few years. It has been shown that prM plays a critical role in viral assembly, maturation, heterodimer formation with the E protein, particle secretion, and virulence




From Mosquitos to Humans: Genetic Evolution of Zika Virus.

Wang L, Valderramos SG, Wu A, Ouyang S, Li C, Brasil P, Bonaldo M, Coates T, Nielsen-Saines K, Jiang T, Aliyari R, Cheng G. *Cell Host Microbe*. 2016 Apr 14. pii: S1931-3128(16)30142-1. doi: 10.1016/j.chom.2016.04.006. [Epub ahead of print]

What made Zika spread so quickly?

- **Hypothesis 2: Immune enhancement***

- Previous flavivirus epidemics – dengue or chikungunya
- Non-neutralizing cross reactive antibodies
- Penetration of cells through Fc receptor
- Increased virus replication
- Zika virus enhanced in culture by heterologous flaviviruses
- Dengue overlap



*Maj Gen Philip K Russell MD

What made Zika spread so quickly?

- Hypothesis 3:
- Zika is going by the same playbook used by dengue and chikungunya
- Part of a general expansion of insect and snail-transmitted diseases into the Americas and Europe



Same thing happening in Southern Europe, Why?


The Anthropocene



The **Anthropocene** is a proposed epoch that begins when human activities started to have a significant global impact on Earth's geology and ecosystems.




Anthropocene forces promoting NTDs



POVERTY: “Blue Marble Health”

- Neglected diseases of the poor living amidst wealth
- A new framework for global science policy and the poverty-related diseases



Blue Marble Health:

The poor living among the wealthy (G20 + Nigeria)



WHO + GBD 2013

- 73-78% Leprosy
 - 61-78% Chagas
 - 60-61% Dengue
 - 57-60% TB
 - 45-67% VL
 - 50-52% Helminths
-
- STH
 - Schistosomiasis
 - Lymphatic Filariasis
 - Onchocerciasis

G20 + Nigeria = 54% Population and 86% Global Economy

Hotez PJ (2013) NTDs V.2.0: "Blue Marble Health"—Neglected Tropical Disease Control and Elimination in a Shifting Health Policy Landscape.

PLoS Negl Trop Dis 7(11): e2570. doi:10.1371/journal.pntd.0002570

<http://www.plosntd.org/article/info:doi/10.1371/journal.pntd.0002570>



NEGLECTED
TROPICAL DISEASES



Baylor
College of
Medicine

Brazil and Blue Marble Health

Introduction to Brazil



LARGEST Economy in Latin America


5th Largest country by land mass + population

7th Largest economy by nominal GDP




Member

BRICS Member



Poverty & Disease NE Brazil:
Schistosomiasis, Leishmaniasis, Chagas, Dengue

Zika Microcephaly cases in NE Brazil



Poverty in Northeastern Brazil



Recife



Salvador de Bahia

Spread of Zika in the Americas




Hotez PJ “Zika is Coming”

The New York Times April 9, 2016

The Most Vulnerable

Predicted locations of the yellow fever mosquito, which transmits the Zika virus and other diseases.



Source: Moritz U. G. Kraemer et al., eLife Sciences; Simon Hay, University of Oxford

By The New York Times

Poverty in Houston TX



Houston's Historic Wards

Anna Grove Photographer


Chagas disease in Texas

New CDC Estimates

- 36,977 cases
- Not including undocumented
- Manne-Goehler J, et al (2016) Estimating the Burden of Chagas Disease in the United States. PLoS Negl Trop Dis 10(11): e0005033. pntd.0005033


| Samples tested | Number tested | Chagas positive N (%) |
|--|---------------|-----------------------|
| Coyote (<i>Canis latrans</i>) | 200 | 16 (8.0%) |
| Shelter dogs (<i>Canis lupus familiaris</i>) < 6 months of age | 209 | 8 (3.8%) |
| Human adult cohort | 841 | 3 (0.36%) |
| <i>Triatoma</i> species vectors | 115 | 65 (56.5%) |

doi:10.1371/journal.pntd.0005074.t001



One Health Interactions of Chagas Disease Vectors, Canid Hosts, and Human Residents along the Texas-Mexico Border
 Melissa N. Garcia et al
 PLoS Negl Trop Dis 2016

WAR & POLITICAL DESTABILIZATION: Ebola



Data are based on reported cases up to the end of 13 September 2014 for Guinea and Sierra Leone. Data for Liberia are based on reported cases up to the end of 9 September 2014. The boundaries and names shown and the designations used on this map do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted and dashed lines on maps represent approximate border lines for which there may not yet be full agreement.



ISIS-Occupied Syria, Iraq, Libya Yemen




- Measles/Polio
- Leishmaniasis
- Schistosomiasis
- Brucellosis
- MERS CoV
- Dengue
- Malaria/TB
- Rift Valley Fever


Clinical Zika

Fever
Maculopapular
Rash (pruritic)
Headache
Conjunctivitis
Retroorbital pain

SYMPTOMS OF ZIKA VIRUS




3 Schematic of the course of human and mosquito infection.



Justin Lessler et al. Science 2016;science.aaf8160



Guillain-Barre syndrome

- Recent history of zika (within 6 days)
- Zika IgM/IgG
- 1/3 respiratory assistance
- Anti-glycolipid antibody (GA1)
- Guillain Barre
 - 1/1,000 French Polynesia
 - 554 cases in Brazil
 - Increase in El Salvador



MICROCEPHALY EP MICROCEPHALY

Microcephaly is the best, a child's head is smaller than expected and is associated with intellectual disability and developmental delay.




Zika Fever Virus from *Aedes aegypti* mosquito is linked to microcephaly birth defect cases, mostly in South America.



Fetal Brain Disruption Sequence

- The fetal brain disruption sequence is a recognizable pattern of defects that includes moderate to profound microcephaly, overlapping sutures, occipital bone prominence, and scalp rugae. The condition is postulated to arise from partial brain disruption...with subsequent fetal skull collapse resulting from decreased intracranial hydrostatic pressure. Recognition of this phenotype is critical because the condition has a uniformly poor prognosis for infants but the recurrence risk in future pregnancies is low.



- Moore, Weaver, Bull et al (1990) J Pediatrics

IS ZIKA MICROCEPHALY RESTRICTED TO BRAZIL?


| Country | Total Zika Cases | Microcephaly Cases |
|------------|------------------|--------------------|
| Brazil | 196,976 | 2,001 |
| Colombia | 95,639 | 42 |
| Venezuela | 58,212 | 0 |
| Martinique | 36,445 | 12 |

PAHO/WHO Mosquito Eradication Campaign 1947-1962



US has no track record in *Aedes aegypti* control

- US did not participate in PAHO Eradication Program
- Began in 1965 halted in 1969




Oxitec



GMO Aedes Mosquitoes “The company's scientists genetically alter the male mosquitoes so that any offspring they father don't develop properly. These genetically modified males mate with the females, which lay dud eggs.”

Zika Vaccine Development Timeline



Sabin PDP Pipeline and Disease Portfolio

2000
to
2004


- Built structure
- Launched Hookworm Program

2004
to
2011

- Expanded Hookworm Program
- Schisto Program
- Relocated to TMC

2011
to
2015

- Added 7 additional programs
- Expansion of capabilities



FIGHTING CRITICAL DISEASES

By Peter Hotez

A Handful Of 'Antipoverty' Vaccines Exist For Neglected Diseases, But The World's Poorest Billion People Need More

ABSTRACT So-called neglected tropical diseases are the most common infections of the world's poor. Almost all of the "bottom billion"—the 1.4 billion people who live below the poverty level defined by the World Bank—suffer from one or more neglected diseases including hookworm infection, sleeping sickness, or Chagas disease. These diseases are actually a cause of poverty because of their adverse effects on child growth and development and worker productivity. Vaccines to combat such diseases have come to be known as "antipoverty vaccines." Unfortunately, the recent surge in the development and delivery of vaccines to combat the major childhood killers—such as pneumococcal pneumonia and measles—has bypassed neglected diseases. Nevertheless, some vaccines for these neglected diseases are now entering the clinical pipeline. In this article I describe how some antipoverty vaccine development is proceeding and offer recommendations for stimulating further development such as through pooled funding for innovation, developing-country manufacturers, and public-private partnerships for product development.

A full year has passed since the launch of the "Decade of Vaccines," which was articulated when the Bill & Melinda Gates Foundation made a 10-year commitment to ensuring the development and delivery of new vaccines for the poorest people living in the world's low- and middle-income countries. Since then, enormous progress has been made in increasing global access to vaccines that combat the great childhood killer diseases such as pneumococcal pneumonia, rotavirus, *Hemophilus influenzae* type b, and measles.

The progress was made possible through enhanced cooperation between the GAVI Alliance, the multinational pharmaceutical companies, and organizations supported by the Bill & Melinda Gates Foundation such as the Program for Appropriate Technology in Health, known as PATH. New financial incentives including a \$1.5 billion advance market commitment have also contributed to the progress.



Lagging far behind these global efforts against the major killer childhood diseases, are parallel activities to produce and deliver a new generation of vaccines for so-called neglected diseases (these are sometimes known as neglected tropical diseases).¹ These neglected diseases are the most common infections of the world's poor, and almost all of the "bottom billion"—that 1.4 billion people who live below the poverty level defined by the World Bank—suffer from one or more of the neglected diseases.

The World Health Organization now identifies severest conditions as "neglected tropical diseases."² The most common neglected diseases are caused by parasitic worms, including hookworm infection, ascariasis (intestinal roundworm), trichuriasis (whipworm), schistosomiasis (bilharzia), lymphatic filariasis (elephantiasis), and onchocerciasis (river blindness); by parasitic protozoa, including Chagas

1080 HEALTH AFFAIRS • JUNE 2011 • 303
Downloaded from <http://aphphelp.aaph.org> by Health Affairs on June 9, 2011
at GEORGE WASHINGTON UNIVERSITY



Therapeutic Chagas Disease Vaccine



Increased Ag-specific IFN γ
 Decreased T. cruzi burden
 Decreased Cardiac fibrosis

Figure 9: Immune response of chronically infected female ICR mice vaccinated therapeutically. IFN γ and IL-4 release from acutely infected and therapeutically vaccinated ICR splenocytes restimulated in vitro with 100 μ g/mL Tc24 protein.

Leishmaniasis Vaccine

- Bivalent recombinant vaccine
 - NH36
 - Sandfly antigens: LJM19 LJM143
 - GLA or CpG



Vaccine 31 (2013) 480–486

Contents lists available at SciVerse ScienceDirect

Vaccine

Journal homepage: www.elsevier.com/locate/vaccine

The potential economic value of a cutaneous leishmaniasis vaccine in seven endemic countries in the Americas

Kristina M. Bacon^{a,b,c}, Peter J. Hotez^d, Stephanie D. Kruchten^{a,b,c}, Shaden Kamhawi^e, Maria Elena Bottazzi^d, Jesus G. Valenzuela^e, Bruce Y. Lee^{a,b,c,*}

^a Public Health Computational and Operational Research (PHCORE), School of Medicine, University of Pittsburgh, 3520 Forbes Avenue, First Floor, Pittsburgh, PA 15213, USA
^b Department of Biomedical Informatics, School of Medicine, University of Pittsburgh, 3520 Forbes Avenue, First Floor, Pittsburgh, PA 15213, USA
^c Department of Epidemiology, Graduate School of Public Health, University of Pittsburgh, 200 Meyran Avenue, Suite 200, Pittsburgh, PA 15213, USA
^d Sabo Vaccine Institute and Texas Children's Hospital Center for Vaccine Development, Departments of Pediatrics and Molecular Virology & Microbiology, National School of Tropical Medicine, Baylor College of Medicine, Houston, TX, USA
^e Vector Molecular Biology Section, Laboratory of Malaria and Vector Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, 12235 Twinbrook Parkway, Room 2E22C, Rockville, MD 20852, USA



U.S. Science Envoy Program



Office of Science and Technology Policy

